A new variant of the virus that causes COVID-19 is rising to prominence within the U.S. as winter sickness season approaches its peak: JN.1, yet another descendent of Omicron.
JN.1 was first detected within the U.S. in September however unfold slowly at first. In current weeks, nonetheless, it has accounted for a rising proportion of check samples sequenced by labs affiliated with the U.S. Facilities for Illness Management and Prevention (CDC), surpassing 20% during the two-week period ending Dec. 9. By some projections, will probably be answerable for at the very least half of recent infections within the U.S. earlier than December ends.
Right here’s what to learn about JN.1.
Is JN.1 extra infectious or extreme than different SARS-CoV-2 variants?
JN.1 is carefully associated to BA.2.86, a fellow Omicron descendent that first popped up within the U.S. this previous summer time. The 2 variants are practically an identical, according to the CDC, aside from a single distinction of their spike proteins, the a part of the virus that permits it to invade human cells.
The truth that JN.1 is answerable for a rising portion of infections suggests it’s both extra contagious or higher at getting previous our our bodies’ immune defenses than earlier iterations of the virus, the CDC says. However there isn’t any proof that it causes extra extreme illness. The World Well being Group (WHO) has not labeled JN.1 a variant of concern—that’s, a brand new pressure of the SARS-CoV-2 virus with potential for elevated severity; decreased vaccine effectiveness; or substantial impacts on well being care supply.
Proper now, there’s nothing that implies JN.1 is any extra harmful than different viral strains, though it might trigger a bump in transmission, the CDC says. Main signs are more likely to be the identical as those from previous variants: a sore or scratchy throat, fatigue, headache, congestion, coughing, and fever.
Do vaccines, exams, and coverings work in opposition to JN.1?
Thus far, the indicators are optimistic. COVID-19 exams and coverings are anticipated to be efficient in opposition to JN.1, the CDC says. And though the latest COVID-19 booster shot was designed to focus on the XBB.1.5 variant, preliminary analysis suggests it also generates antibodies that work against JN.1, albeit fewer of them. (As ever, vaccines is not going to completely block JN.1 infections, however ought to scale back the chance of dying and extreme illness.)
In a Dec. 13 statement, WHO’s professional COVID-19 vaccine advisory group beneficial sticking with the present XBB.1.5 vaccines, since they appear to offer at the very least some cross safety.
Will JN.1 trigger a COVID-19 surge within the U.S.?
The CDC now not logs each single COVID-19 prognosis within the U.S., however different indicators of illness are up. Wastewater surveillance data counsel there’s loads of COVID-19 going round, particularly in the Northeast. Hospitalizations are additionally on the rise, though far fewer people are being admitted than presently final 12 months. Dying charges are presently secure, although they have a tendency to lag barely behind hospitalizations.
It’s too quickly to say whether or not JN.1 will trigger a major spike in circumstances, though its ascendance throughout the busy holiday travel and gathering season might gasoline elevated transmission. “Proper now, we have no idea to what extent JN.1 could also be contributing to those will increase or doable will increase via the remainder of December like these seen in earlier years,” the CDC wrote in a Dec. 8 update on the variant.
The perfect defenses in opposition to JN.1—and different variants of SARS-CoV-2—stay getting vaccinated, masking in crowded indoor areas, and limiting publicity to individuals who could have been contaminated.
Extra Should-Reads From TIME
